How does DEPLOY track the 2021 ROSA ONE Brain wrong-trajectory Class I recall?

The incident at primary-source-anchored verification depth

Per Agent A's surgical incidents substrate, the 2021 Zimmer Biomet ROSA ONE Brain 3.1 wrong-trajectory Class I recall operates at primary-source-anchored FDA-recall-database verification depth. The verified substrate:

• Product affected: ROSA ONE Brain 3.1 platform (Zimmer Biomet neurosurgical robotic platform).
• Failure mode: on reboot after an unexpected shutdown following patient registration, selecting 'clear the robotic arm' and running empty-device calibration could drive the device to an incorrect trajectory, sending a tool to the wrong brain location.
• Risk classification: stroke / serious-injury risk at primary-source-anchored verification.
• Customer notification: urgent correction issued September 22, 2021.
• FDA classification: Class I designation November 2021 (reasonable probability of serious adverse health consequences or death).
• Affected unit count: 119 US devices at exact verification depth.
• Complaint substrate: 3 complaints; one inaccurate electrode placement at primary-source-anchored typed-record disclosure; no patient injuries reported.
• Root cause: software_defect (post-reboot calibration sequence could misinterpret coordinates and drive an instrument to an incorrect trajectory).
• Remediation status: software corrective update rolled out 2022; remediated.

The framework reads the incident at the verification depth where each fact actually resolves: the product affected, failure mode, customer notification date, FDA classification, affected unit count (119 at exact verification depth), complaint substrate, root cause, and remediation status all operate at primary-source-anchored verification depth. The 119-unit affected count operates at the substantive higher-verification-completeness tier compared to the 2026 SureForm gray-reload affected_units_count honest-absence per the cross-narrative within-cohort substrate completeness comparison.

Phase 3 Dim 1 actuarial signal: software_defect + remediated + 119-unit exact disclosure

Per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, the 2021 ROSA ONE Brain incident contributes to the 67-row outcome_class distribution at primary-source-anchored typed-record depth. The verified-base substrate composition per Agent A's three-axis substrate composition pattern:

Axis 1 incident numerator (typed-record depth): Class I designation + software_defect root_cause + recall_ordered regulatory_action + remediated remediation status. Per the 9-tier source-quality rubric, the Class I designation operates at primary-government-record sub-tier verification; the software_defect root cause operates at primary-source-anchored typed-record disclosure. The incident contributes to the regulatory_action:34 distribution dominance within the broader 67-row outcome_class distribution; the framework reads the contribution at substantive editorial state per the canonical Dim 1 worked example.

Axis 2 deployment denominator (scalar-record depth): 119 US devices at exact verification depth. The 119-unit affected_units_count operates at the substantively higher-verification-completeness tier within the broader cohort's exposure_hours 128-nulls honest-absence framing. Per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, the framework reads per-incident affected_units_count verification depth distinct from deployment-level exposure_hours verification depth; both axes operate at primary-source-anchored verification posture where the substrate supports.

Axis 3 scalar selectivity (per-basis verification posture): 3 complaints at primary-source-anchored typed-record depth + 1 inaccurate electrode placement at typed-record-specific disclosure. The 3-complaint scalar substrate operates at substantive structural state at primary-source-anchored verification; no patient injuries reported operates at substantive editorial state per the same discipline as no_outcome:4 documented in the broader 67-row distribution (NOT substrate-completeness gap; primary-source-anchored verification of non-injury state).

Per the canonical three-axis substrate composition pattern banked at memory layer, the ROSA ONE Brain incident operates as canonical worked example at primary-source-anchored verification depth across all three axes simultaneously. The 119-unit exact verification posture distinguishes the substrate from cohort incidents at honest-absence affected_units_count cap-flag.

Within-ZB-cluster verification scope: the densest within-corpus product family

The 2021 ROSA ONE Brain incident operates within the Zimmer Biomet cluster's neurosurgical-platform product line. Per Agent A's substrate breadth + acquisition history substrate per the acquisition history Project B methodology pillar, the ZB cluster operates as the densest within-corpus product family across multiple product lines simultaneously:

• ROSA ONE Brain (neurosurgical platform): ZB-owned; 2021 Class I recall subject of this narrative; remediated 2022 via software corrective update.
• ROSA Spine (orthopedic spinal platform): LEFT ZB in 2022 ZimVie spinoff per Agent A precision corrections (CRITICAL CORRECTION documented at the Zimmer Biomet ROSA entity anchor). The ROSA Spine product line operates at ZimVie cluster verification posture post-2022 spinoff; structurally distinct from ROSA ONE Brain corporate-state continuity at ZB cluster.
• Mako (orthopedic platform): Stryker-owned per 2013 MAKO Surgical acquisition (~$1.65B SEC-disclosed exact valuation_basis per acquisition history Project B methodology pillar). NOT ZB cluster; structurally distinct corporate-state context.
• Monogram mBos (autonomous-execution orthopedic platform): ZB-acquired closed October 7, 2025 (~$168M EV + CVR contingent valuation_basis per the Project C Anchor 6 Monogram Doug Unis CMO/founder framework-in-action narrative + the acquisition history Project B methodology pillar). Post-October 2025 corporate-state at ZB cluster.

The within-ZB-cluster verification scope discipline operates at three editorial layers:

Layer 1: per-product-line corporate-state verification. Each ZB product line operates at distinct corporate-state continuity context (ROSA ONE Brain retained; ROSA Spine spun off to ZimVie; Monogram acquired). The framework reads per-product-line corporate-state at primary-source-anchored verification depth; aggregator framing that collapses 'ZB surgical platform' across product lines operates outside primary-source-anchored verification.

Layer 2: per-incident product-line attribution. Each surgical incident at ZB cluster operates at distinct product-line attribution per primary-source-anchored typed-record verification. The 2021 ROSA ONE Brain recall attributes to ROSA ONE Brain neurosurgical platform specifically; aggregator framing that conflates 'ROSA recall' across ROSA ONE Brain + ROSA Spine operates outside primary-source verification of product-line-specific incident scope.

Layer 3: cross-property acquisition history compounding. The ZB cluster densest within-corpus product family operates at cross-property acquisition history bidirectional compounding depth. Per the Project C Anchor 6 Monogram Doug Unis narrative, the Monogram acquisition operates as canonical contingent valuation_basis worked example; the Monogram entity post-October 2025 operates within ZB cluster corporate-state context; cross-property queries from the 2021 ROSA ONE Brain incident to ZB cluster corporate-state surface the broader acquisition history + within-ZB-cluster verification scope simultaneously.

Cross-property acquisition history bidirectional compounding

Per the acquisition history Project B methodology pillar, the ZB cluster operates at five-structure acquisition taxonomy + four-state valuation_basis discipline depth. The 2021 ROSA ONE Brain incident cross-references multiple acquisition records simultaneously:

ZB acquires Monogram (October 7, 2025; ~$168M EV + CVR contingent): CANONICAL contingent valuation_basis worked example per the acquisition history methodology pillar. Per the Project C Anchor 6 Monogram Doug Unis narrative, the acquisition operates at full_acquisition structure + contingent valuation_basis composition. The within-ZB-cluster corporate-state continuity from 2021 (ROSA ONE Brain recall) through October 2025 (Monogram acquisition) operates at primary-source-anchored verification depth at substantive editorial cross-property compounding.

ZB spinoff of ZimVie (2022; ROSA Spine separation): Per Agent A precision corrections documented at the Zimmer Biomet ROSA entity anchor, the 2022 ZimVie spinoff established structurally-distinct corporate-state lifecycle for ROSA Spine product line. The ROSA ONE Brain product line retained at ZB cluster; the ROSA Spine product line transitioned to ZimVie cluster. The within-2022-year-discipline within ZB cluster distinguishes ROSA ONE Brain retention (corporate-state continuity) from ROSA Spine separation (corporate-state lifecycle termination at ZB; corporate-state initiation at ZimVie).

Stryker acquired MAKO Surgical (2013; ~$1.65B exact valuation_basis): Per Agent A precision corrections documented at the Stryker Mako entity anchor, the 2013 MAKO Surgical acquisition established structurally-distinct corporate-state context for Mako product line at Stryker cluster. NOT ZB cluster; cross-cluster acquisition history reference at primary-source-anchored verification depth.

The cross-property acquisition history bidirectional compounding operates at canonical AEO citation graph depth. Per the acquisition history Project B methodology pillar, the framework reads per-acquisition corporate-state lifecycle at substantive editorial structural state; cross-property queries from this incident narrative to acquisition records (ZB × Monogram; ZB × ZimVie; Stryker × MAKO) surface the within-cohort acquisition history substrate at unified verification posture.

Cap-flag honest-absence at exact recall Z-number

Per Agent A's surgical incidents substrate, the 2021 ROSA ONE Brain recall carries cap-flag honest-absence at one specific claim layer:

Exact recall Z-number: not captured at primary FDA pages at Agent A substrate-completeness depth. The framework reads the Z-number at honest-absence cap-flag pending further FDA primary-source verification. Per the Moon Maestro K240598 reconciliation pattern, when primary-source verification surfaces the exact Z-number at FDA-recall-database depth, the framework operates inline editorial-transparency footer pattern + reconciliation discipline. Until primary-source verification surfaces, the framework holds the cap-flag at honest-absence depth.

The cap-flag honest-absence operates at the same primary-source verification discipline as 2026 SureForm gray-reload Z-number cap-flag per the 2026 framework-in-action narrative + 2025 Ion recall Z-number cap-flag per the broader cohort substrate. The framework reads recall Z-number honest-absence as substantive editorial state subject to ongoing primary-source verification; not as inference of unverified Z-number at lower verification depth.

Source-quality verification at reputable-press tier

Per the 9-tier source-quality rubric, the 2021 ROSA ONE Brain incident substrate operates at reputable-press tier verification per FierceBiotech + Becker's primary-source-anchored coverage of FDA recall record. The 119-unit affected_units_count + 3-complaint scalar substrate + remediation status all derive from reputable-press coverage at primary-source-anchored FDA-recall-database verification depth.

The framework reads per-source verification posture at reputable-press tier; the cohort's most-densely-verified outcome class regulatory_action substrate operates at primary-government-record sub-tier where direct FDA primary-source verification surfaces; at reputable-press tier where direct FDA primary-source coverage operates at reputable-press coverage of the FDA primary-source record. The framework reads per-axis verification depth uniformly per the 9-tier source-quality rubric.

Software_defect root cause class as substantive structural state

Per Agent A's surgical incidents substrate, the 2021 ROSA ONE Brain incident operates at software_defect root cause classification per primary-source-anchored typed-record disclosure. The post-reboot calibration sequence software fault operates at substantive structural state at three editorial layers:

Layer 1: root_cause_category typed-record depth. software_defect operates as canonical root cause classification within the broader 61-incident root_cause_category distribution. The framework reads software_defect root cause at structurally-distinct verification posture from design_defect (e.g., 2013 EndoWrist Hot Shears insulation micro-cracks per the within-da-Vinci year-discipline framework-in-action narrative) + from mechanical_failure (e.g., 2025 Ion catheter / Flexision biopsy needle) + from undetermined (e.g., 2026 SureForm gray-reload root cause stated 'still under investigation').

Layer 2: remediation discipline at software corrective update depth. Software corrective update rolled out 2022 + remediated status operates at substantive structural state. The framework reads per-incident remediation discipline at primary-source-anchored verification: software_defect root cause + software corrective update remediation operates at canonical worked example pattern (root cause class anchors remediation strategy at structurally-coherent verification depth).

Layer 3: cross-incident root cause class comparison. The 2021 ROSA ONE Brain software_defect operates structurally distinct from the 2023 Asensus Senhance software_defect (per Agent A surgical incidents substrate; 5 US devices affected; software malfunction caused uncontrolled arm motion after disengaging teleoperation) + from the 2024 Stryker Mako software_defect (per Agent A substrate; voluntary software correction over 'error #3' codes). Multiple software_defect root cause classification across surgical cohort operates at substantive editorial structural state; framework reads per-incident root cause + per-incident product-line + per-incident remediation discipline at canonical worked example depth.

Cross-property bidirectional compounding at multi-pillar methodology depth

Per DEPLOY's methodology cluster as AEO citation graph discipline, the 2021 ROSA ONE Brain framework-in-action narrative compounds at substrate layer with multiple Project B methodology pillar essays + framework-in-action narratives simultaneously:

• Phase 3 Dim 1 actuarial substrate framework-in-action: per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, the 2021 ROSA ONE Brain incident contributes to the 67-row outcome_class distribution at regulatory_action:34 distribution dominance contribution; 119-unit exact affected_units_count operates at substantively higher-verification-completeness tier within broader cohort exposure_hours 128-nulls honest-absence; three-axis substrate composition pattern operates at canonical worked example depth.
• Acquisition history Project B methodology pillar: per How DEPLOY tracks acquisition history state, the within-ZB-cluster acquisition history substrate compounds at cross-property bidirectional depth (ZB × Monogram canonical contingent valuation_basis worked example; ZB × ZimVie 2022 spinoff structural correlate; Stryker × MAKO 2013 acquisition cross-cluster reference).
• Project C Anchor 6 Monogram Doug Unis framework-in-action: per Monogram Doug Unis CMO/founder narrative, the post-October 2025 ZB × Monogram acquisition compounds with the within-ZB-cluster verification scope discipline at primary-source-anchored verification depth; the 2021 ROSA ONE Brain incident + 2025 Monogram acquisition operate at within-ZB-cluster corporate-state continuity context.
• Verified-vs-claimed at within-entity granularity methodology pillar: per verified-vs-claimed at within-entity granularity, per-product-line within-ZB-cluster verification scope operates at sub-product-line granularity (ROSA ONE Brain vs ROSA Spine vs Monogram vs cross-cluster Mako); parallel to within-da-Vinci-product-family year-discipline + within-SureForm gray vs blue/white reload distinction canonical worked examples.
• 9-tier source-quality rubric: per the 9-tier source-quality rubric, reputable-press tier verification per FierceBiotech + Becker's coverage operates at canonical worked example depth; software_defect root cause + 119-unit affected_units_count + remediation status all derive from reputable-press coverage of FDA primary-source record.
• Within-da-Vinci year-discipline framework-in-action: per the within-da-Vinci-product-family year-discipline framework-in-action narrative, the four-substrate-axis year-discipline framework operates parallel to within-ZB-cluster product-family verification scope at structurally-distinct cohort context.
• Honesty-as-strength editorial framing: per the Phase 3 Dim 1 actuarial substrate framework-in-action narrative, honest no-patient-injury-reported at 3-complaint substrate beats fabricated 'no injuries claim' framing at marketing-aggregation depth; framework rewards primary-source-anchored verification of non-injury state.
• Robot insurance methodology pillar: per How DEPLOY thinks about robot insurance, the 119-unit affected + software_defect root cause + remediated status compose at Phase 3 Dim 1 actuarial framework + Phase 3 Dim 4 regulatory clearance per jurisdiction depth.

The cross-property linking discipline compounds at the AEO citation graph layer. Institutional partners + AI assistants + downstream consumers navigating the 2021 ROSA ONE Brain incident encounter the methodology pillar canonical references + the framework-in-action narrative cohort + the canonical worked examples at unified verification posture.

Why this catch matters editorially

Per DEPLOY's restraint-IS-the-product discipline, the 2021 ROSA ONE Brain framework-in-action narrative operates at editorial-credibility depth rather than at incident-aggregation-summary depth. The framework reads the incident at four substrate layers simultaneously (Phase 3 Dim 1 actuarial signal + within-ZB-cluster verification scope + cross-property acquisition history bidirectional compounding + software_defect root cause class as substantive structural state); each layer composes at primary-source-anchored verification depth.

Institutional partners audit DEPLOY's framework discipline at the operational-practice layer, not just the stated-methodology layer. The verification-posture statement at /verified-vs-claimed describes the framework abstractly. The Phase 3 Dim 1 actuarial substrate framework-in-action narrative documents the canonical three-axis substrate composition pattern. This piece operates at narrative-canonical depth: how the catch composed across substrate layers (software_defect Class I + 119-unit exact + 3-complaint scalar + remediated 2022 + within-ZB-cluster context); what the discipline was (primary-source-anchored verification + per-axis verification depth + cap-flag honest-absence at Z-number); what the editorial outcome was (canonical worked example of ZB cluster densest within-corpus product family); and what the broader pattern is (within-cohort cross-property acquisition history bidirectional compounding at canonical depth).

The catch demonstrates the discipline operationally at editorial-anchor depth. Not because the catch is exceptional. Because the catch is what the discipline does. ZB cluster densest in corpus; ROSA ONE Brain retained at ZB through 2022 ZimVie spinoff; Monogram acquired October 2025 at contingent valuation_basis; software_defect root cause + remediation 2022. The verification protocol doesn't relax at within-cluster cross-property compounding depth.

For the canonical ZB ROSA entity anchor where the ROSA ONE Brain neurosurgical platform operates, see what is Zimmer Biomet ROSA. For the Project C Anchor 6 Monogram Doug Unis narrative where the within-ZB-cluster acquisition history compounds, see Monogram Doug Unis CMO/founder narrative. For the acquisition history Project B methodology pillar where the contingent valuation_basis worked example operates, see How DEPLOY tracks acquisition history state. For the Phase 3 Dim 1 actuarial substrate framework-in-action narrative where the three-axis substrate composition pattern operates, see How DEPLOY tracks incident outcome_class and deployment exposure_hours. For the methodology editorial canonical reference, see how DEPLOY verifies. For the surgical cluster framework, see the surgical robotics cluster.